Wasatch Advisors’s Journey Medical DERM Stock Holding History

Wasatch Advisors’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.8M	Sell	2,449,253 -409,677	-14%	-$2.85M	0.12%	118
2026 Q2	$20.2M	Buy	2,858,930 +725,560	+34%	+$4.14M	0.13%	118
2026 Q1	$10M	Buy	2,133,370 +817,095	+62%	+$6.34M	0.07%	129
2025 Q4	$10.1M	Buy	1,316,275 +10,003	+0.8%	+$78.4K	0.06%	147
2025 Q3	$9.3M	Buy	1,306,272 +154,213	+13%	+$1.12M	0.05%	154
2025 Q2	$8.27M	Buy	1,152,059 +221,456	+24%	+$1.53M	0.04%	165
2025 Q1	$5.49M	Buy	+930,603	New	+$4.58M	0.03%	182

Other funds holding DERM

PAM

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

Salem Investment Counselors Winston Salem, North Carolina $4.01B AUM 48.23% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Wasatch Advisors's DERM Position: Q3 2026 in Review

Wasatch Advisors reduced its Journey Medical (DERM) stake by 14% in Q3 2026, selling an estimated $2.85M and leaving 2,449,253 shares worth $16.8M. The position accounts for 0.12% of the portfolio, ranked #118.

Wasatch Advisors first reported a position in DERM in Q1 2025 and has held it in 7 quarters since. The position peaked at $20.2M in Q2 2026. 4 funds tracked by Wall St. Rank hold DERM as of Q3 2026.

Wasatch Advisors held 2,449,253 shares of Journey Medical worth $16.8M as of Q3 2026.
Wasatch Advisors sold 409,677 Journey Medical shares in Q3 2026, an estimated $2.85M.
Journey Medical made up 0.12% of Wasatch Advisors's portfolio in Q3 2026, its #118 holding.
Wasatch Advisors first reported a position in Journey Medical in Q1 2025 and has held it in 7 quarters since.
Wasatch Advisors's Journey Medical position peaked at $20.2M in Q2 2026.
4 funds tracked by Wall St. Rank held Journey Medical as of Q3 2026.

Based on Wasatch Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.